CNBC
01 Jul 2026, 22:50 UTC · 3h ago
Jim Cramer says this former Covid market darling is finally investable again
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
CNBC
01 Jul 2026, 22:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Moderna has late-stage clinical trial results for a melanoma combination therapy with Merck expected later this year. — Late-stage trial results for a major oncology target are high-volatility catalysts that can fundamentally re-rate a biotech stock.
+0.60The FDA advisory committee has recommended approval for Moderna's experimental flu vaccine, with a regulatory decision due August 5. — A positive regulatory decision creates a new immediate revenue stream and validates the company's pipeline expansion.
+0.40Moderna is expanding its pipeline into oncology, with mid and late-stage trials targeting melanoma, lung, renal, and bladder cancers. — Diversification into cancer therapies reduces reliance on infectious disease vaccines, though long-term profitability remains years away.
+0.30Continue reading
6 related stories
Search tags
The European Commission has approved Moderna's combination Covid and flu vaccine. — Market expansion into combined vaccines provides a steady growth path to offset the decline in standalone Covid vaccine demand.
+0.20Which stocks this story touches
The article highlights an expanding pipeline, a roadmap to profitability, and positive momentum in oncology and flu vaccines.
Mentioned positively in the context of a late-stage study involving its drug Keytruda in combination with a Moderna therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
10h ago
